Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ALTERITY-THERAPEUTICS-LIM-57291688/news/Alterity-Therapeutics-Phase-2-Data-Monitoring-Committee-Recommends-Continuing-Clinical-Trial-as-Plan-46664553/?utm_source=whatsapp&utm_medium=social&utm_campaign=share